A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment,
crossover study in healthy male and female subjects. This study is intended to assess the
relative bioavailability between the fixed dose combination (FDC, i.e. verinurad/allopurinol
FDC capsule 12/300 mg) and free combination formulations of verinurad (i.e. verinurad
prolonged release Hydroxypropyl methylcellulose [HPMC] capsule 12 mg) and allopurinol (i.e.
allopurinol table 300 mg) in fasted and fed conditions. The study will also assess the
relative bioavailability between a formulation only containing verinurad (i.e. verinurad
prolonged release gelatin capsule 12 mg) and the FDC capsule.